medigraphic.com
Órgano Oficial del Instituto de Ciencias de la Salud, Hospital Escuela y Facultad de Medicina-Xalapa

2004, Number 2

<< Back Next >>

Rev Med UV 2004; 4 (2)

Adherencia al Tratamiento Antirretroviral en los Pacientes con VIH/ SIDA con y sin Grupo de Autoayuda

Gutiérrez BGA, Olaíz NMA, García SNJ

Language: Spanish
References: 22
Page: 7-15
PDF size: 681.78 Kb.


ABSTRACT

TITLE: Antiretroviral treatment adherence in patients with HIV/ AIDS, with or without self-help group. OBJECTIVE: To determine the antiretroviral treatment adherence in patients with HIV/AIDS attending external consultation as compared with Hospital de Especialidades número 14 (Specialties Hospital number 14) self-help group. MATERIAL AND METHODOLOGY: 52 patients with HIV/AIDS where included, these were divided into two groups: group 1 (n=12) patients who attend both, external consultation and self-help group, and group 2 (n=40) those who just attend external consultation. Demographic data were taken and patients answered a self-reported adherence survey (evaluated as follows: number of ingested doses divided by the number of prescribed doses multiplied by 100) and the Medication Adherence Rating Scale (MARS) and the Hamilton Depression Rating Scale. The Mann-Whitney U, Chi squared and Wilcoxon tests were used in the statistical analysis. RESULTS: The average age in both groups was 38.76 ± 9.3 years with an evolution of HIV/AIDS of 5.17 ±3.4 years. The number of CD4+ cells for group 1 was 412 ±202 cells 106/L and group 2 was 312 ± 183 cells 106/L with a pns. The viral load of group 1 was1046 ± 1433.1 copies/mL and group 2 was 61640 ± 137768 copies/ mL with a p‹0.05 (See figure 3). The treatment adherence according to the formula for group was 1 98.2 ± 1.7 and for group 2 was 96.7 ± 4.07 with a pns (See figure 1). The Medication Adherence Rating Scale (MARS) for group 1 was 0.57 ± 0.35 and for group 2 was 0.40 ± 0.32 with a pns (See figure 2). In the Hamilton Scale, the patients without depression in group 1 were 83% (10) whereas in group 2 were 72.5% (29), and the percentage with some level of depression in group 1 was 17% (2) and group 2 was 27.5% (11) with a pns. CONCLUSIONS: The antiretroviral treatment adherence in both groups presents no significant difference. In the group 1 the medication intake is carried out in the correct way in a higher percentage in comparison to group 2 without self-help.


REFERENCES

  1. Nieto & Santoscoy. Tratamiento antirretroviral en el adulto con VIH/SIDA. Adherencia al tratamiento antirretroviral. 2004;(9):237- 255.

  2. Bartlett JG. The Johns Hopkins Hospital 2003 Guide to MEDICAL CARE of PATIENTS WITH HIV INFECTION 11 th Edition.

  3. Torres I, Ruiz A. Intervención para mejorar el apego al tratamiento en pacientes con VIH. Medicina Interna de México 2003; 19 (5): 280-285.

  4. Ananworanich J, Nuesch R, Le Braz M, et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17 (15): F33-F37.

  5. Walsh C, Mandalia S, Gazzard BG. Responses to a 1-month self-report on adherence to antiretroviral therapy are consistent with electrnic data and virologic out-come. AIDS 2002; 16: 269-77.

  6. Kleeberger C, Buechner J, Palella F et al. Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS 2004; 18 (4): 683-688.

  7. Nemes M, Carvallo H, Souza, Antiretroviral therapy adherence in Brazil. AIDS 2004; 18 (S3): S15-S20.

  8. Flaks R, Burman W, Gourley P, Rietmeijer C, Cohn D. HIV Transmission Risk Behavior and Its Relation to Antiretroviral Treatment Adherence. Sexually Transmitted Diseases. 2003; (5): 399-404.

  9. Starace F, Ammassari A, Trotta M, et al. Depression Is a Risk Factor for Suboptimal Adherence to Highly Active Antiretroviral Therapy. JAIDS 2002; 31: S136-S139.

  10. Murri R, Antinori A, Ammassari A. Physican Estimates of Adherence and the Patient-Physician Relationship as a setting to Improve Adherence to Antiretroviral Therapy. JAIDS 2002; 31: S158-S162.

  11. Bangsberg, D y col. Assessment of Adherence to HIV Antiretroviral Therapy. JAIDS 2001; 26 (5): 435-442.

  12. Wood E, Hogg R, Yip B et al. Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 x 109 cells/L. Annals of Internal Medicine 2003; 139 (10): 810-816.

  13. Guía de Manejo Antirretroviral de las personas que viven con el VIH/ SIDA. CENSIDA. 2004.

  14. Guía de Temas Selectos para la atención de pacientes con infección por el VIH/ SIDA. MMVIH. Edición 2001.

  15. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000; 42: 241-247.

  16. Phillips A, Cozzi A, Lampe F, Sabin MJ. When should antiretroviral therapye started for HIV infection, Interpreting the evidence from observational studies. AIDS 2003; 17: 1863-1869.

  17. Lawrence J, Mayers D, Huppler K, et al. Structured Treatment Interruption in Patients with Multidrug-Resistant Human Immunodeficiency Virus. N Engl Med 2003; 349: 837-46.

  18. Bernard H, Beware of Drug Holidays before HIV Salvage Therapy. N Engl Med 2003; 349: 827-828.

  19. Hammer S, Vaida F, Bennett K, et al. Dual vs Single Portease Ihibitor Therapy Following Antiretroviral Treatment Failure. JAMA 2002; 288 (2): 169-180.

  20. Hirsch M, Brun-Vézinet F, D’ Aquila R, et al. Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection. JAMA 2000; 283 (18): 2417-2426.

  21. Carpenter C, Cooper D, Fischl M, et al. Antiretroviral Therapy in Adults. JAMA 2000; 283 (3): 381-390.

  22. McNabb J, Nicolau D, Stoner J, Ross J. Patterns of adherence to antiretroviral medications: the value of electronic monitoring. AIDS 2003;17: 1763-1767




2020     |     www.medigraphic.com